The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness.
Kaspar KeledjianOrest TsymbalyukStephen Andrew SemickMitchell MoyerSerban NegoitaKevin KimSvetlana IvanovaVolodymyr GerzanichJ Marc SimardPublished in: PloS one (2020)
This novel GWI model recapitulates critical neurofunctional abnormalities reported by Veterans with GWI. Concurrent prophylactic treatment with ROSI was beneficial in this model.